Even minor reductions in COVID transmission rates due to early isolation would justify the additional costs associated with the policy.
- Associate Professor in Health Economics, Flinders University
Most of us would agree that cancer drugs should be listed on the PBS, no matter how dear. But our health system can’t afford all of them. How then are decisions about which drugs to subsidise made?
Contact Hossein for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Website
- Article Feed
-
- Joined

